Immupharma PLC Interim Board Change (2760M)

TIDMIMM

RNS Number : 2760M

Immupharma PLC

06 May 2015

 
    6 May 2015 
 

INTERIM BOARD CHANGE

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that Dr Franco Di Muzio, senior Non-Executive Director will take on the role of Chairman on an interim basis. Due to recent ill health, Richard Warr, Executive Chairman, has taken a leave of absence in order to make a full recovery.

Commenting on the announcement, Dr Franco Di Muzio said:"As the Senior Non-Executive Director of ImmuPharma since its formation, I have an in-depth knowledge of the Company and would like to assure shareholders of my commitment to fulfilling the responsibilities required in the position of Interim Chairman during this period. The Board would like to wish Richard a speedy recovery."

   -      Ends - 

For further information please contact:

 
                                           + 44 (0) 20 
 ImmuPharma plc                              7152 4080 
 Dimitri Dimitriou, Chief Executive 
  Officer 
 Lisa Baderoon, Head of Investor         + 44 (0) 7721 
  Relations                                     413496 
 
 Panmure, Gordon & Co., NOMAD &        [phone] 
  Broker                                          2500 
  Hugh Morgan, Fred Walsh, Duncan 
    Monteith (Corporate Finance) 
   Charles Leigh-Pemberton (Corporate 
    Broking) 
 
 
 

Notes to Editors:

Dr Franco Di Muzio, Senior Non-Executive Director

Dr Di Muzio has 40 years' experience in the pharmaceutical and other industries, encompassing international management experience in business development, strategic marketing, international finance, M & A and re-engineering businesses. After graduating in Economics and Business in 1963, Dr Di Muzio worked for Colgate Palmolive and Nestle before joining Squibb (now Bristol Myers Squibb) for eight years. Dr Di Muzio became Executive Vice President of BMS' medical equipment and products division, Weck International Inc., in charge of Europe, Asia, Middle East and Africa. In 1990, he joined Glaxo Wellcome plc. (now GlaxoSmithKline plc) in London as Area Managing Director and Head of all GW's business in the Middle East, Africa and Turkey. Following early retirement from Glaxo Wellcome, in the beginning of 1998, he joined Alza International, the then world leader in drug delivery systems, as Managing Director, based in London, in charge of the company's business expansion in all markets outside the US and remained there until the end of 2000.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOALLFLAEVIEIIE